Evidence map›Paper›PMID 30387242›Full record

ArticleJournal of applied clinical medical physics2019

Longitudinal assessment of anchored transponder migration following lung stereotactic body radiation therapy.

Andrew M McDonald, Tyler Colvin, D Hunter Boggs, Sharon A Spencer, Richard A Popple, Ravinder Clayton, Douglas Minnich, Michael C Dobelbower

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of applied clinical medical physics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Augmented reality-guided positioning system for radiotherapy patients.Journal of applied clinical medical physics · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Andrew M McDonaldDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Tyler ColvinUniversity of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
D Hunter BoggsDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Sharon A SpencerDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Richard A PoppleDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Ravinder ClaytonDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Douglas MinnichGrandview Medical Center, Thoracic Surgery, Birmingham, AL, USA.
Michael C DobelbowerDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
University of Alabama at Birmingham · USGrandview Medical Center · US

Funding

Varian Medical Systems
6 · The paper itself

Abstract

purposeTo assess the long-term stability of the anchored radiofrequency transponders and compare displacement rates with other commercially available lung fiducial markers. We also sought to describe late toxicity attributable to fiducial implantation or migration. MATERIALS AND

methodsThe transponder cohort was comprised of 17 patients at our institution who enrolled in a multisite prospective clinical trial and underwent bronchoscopic implantation of three anchored transponders into small (2-2.5 mm) airways. We generated a comparison cohort of 34 patients by selecting patients from our institutional lung SBRT database and matching 2:1 based on the lobe containing tumor and proximity to the bronchial tree. Assessment of migration was performed by rigidly registering the most recent follow-up CT scan to the simulation scan, and assessing whether the relative geometry of the fiducial markers had changed by more than 5 mm. Toxicity outcomes of interest were hemoptysis and pneumothorax.

resultsThe median follow-up of patients in the transponder cohort was 25.3 months and the median follow-up in the comparison cohort was 21.7 months. When assessing the most recent CT, all fiducial markers were within 5 mm of their position at CT simulation in 11 (65%) patients in the transponder group as compared to 23 (68%) in the comparison group (P = 0.28). One case of hemoptysis was identified in the transponder cohort, and bronchoscopy confirmed bleeding from recurrent tumor; no cases of hemoptysis were noted in the comparison cohort. No case of pneumothorax was noted in either group.

conclusionNo significant difference in the rates of fiducial marker retention and migration were noted when comparing patients who had anchored transponders placed into small airways and a 2:1 matched cohort of patients who had other commercially available lung fiducial markers placed. In both groups, no late or chronic toxicity appeared to be related to the implanted fiducial markers.

Indexed as

Electromagnetic PhenomenaProstheses and ImplantsRadiosurgeryFiducial MarkersHumansLongitudinal StudiesLung NeoplasmsPrognosisProspective StudiesRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedTherapy, Computer-Assistedelectromagnetic transponder beaconsimage guided radiation therapylung cancerstereotactic body radiation therapy

Identifiers

PMID30387242
PMCPMC6333116
OpenAlexW2899419937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.